Back to Search
Start Over
CDK 4/6 inhibitors as single agent in advanced solid tumors
- Source :
- Frontiers in Oncology, Frontiers in Oncology, Vol 8 (2018)
- Publication Year :
- 2018
-
Abstract
- Cyclin-dependent kinases (CDK) 4/6 inhibitors, namely abemaciclib, palbociclib, and ribociclib, interfere with cell cycle progression, induce cell senescence and might promote cancer cell disruption by a cytotoxic T cells-mediated effect. Phase III randomized clinical trials have proven that CDK4/6 inhibitors (CDK4/6i) in combination with several endocrine agents improve treatment efficacy over endocrine agents alone for hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (MBC). Based on such results, these combinations have been approved for clinical use. Preclinical studies in cell cultures and mouse models proved that CDK4/6i are active against a broad spectrum of solid tumors other than breast cancer, including liposarcoma, rhabdomyosarcoma, non-small cell lung cancer, glioblastoma multiforme, esophageal cancer, and melanoma. The role of CDK4/6i in monotherapy in several solid tumors is currently under evaluation in phase I, II, and III trials. Nowadays, abemaciclib is the only of the three inhibitors that has received approval as single agent therapy for pretreated HR+ HER2- MBC. Here we review biological, preclinical and clinical data on the role of CDK4/6 inhibitors as single agents in advanced solid tumors.
- Subjects :
- 0301 basic medicine
Cancer Research
Review
Palbociclib
Cell cycle
lcsh:RC254-282
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Breast cancer
Cyclin-dependent kinase
Ribociclib
Solid tumors
Medicine
Rhabdomyosarcoma
Abemaciclib
neoplasms
Cyclin-dependent kinases
Oncology
biology
business.industry
abemaciclib, cell cycle, cyclin-dependent kinases, palbociclib, ribociclib, solid tumors
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Metastatic breast cancer
030104 developmental biology
chemistry
030220 oncology & carcinogenesis
Cancer cell
Cancer research
biology.protein
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Frontiers in Oncology, Frontiers in Oncology, Vol 8 (2018)
- Accession number :
- edsair.doi.dedup.....e206350487e5e00c57080d4482f21866